As of November 10, 2026, Trevi Therapeutics, Inc. is a publicly traded company (Nasdaq: TRVI). The largest holder reporting an active stake on Schedule 13D is New Enterprise Associates 16, L.P., at 10.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (8.8%), Frazier Life Sciences Public Fund, L.P. (7%), BlackRock (6.9%) (Schedule 13D/A, May 7, 2026).
Is this your company?
About to sign with, pay or invest in Trevi Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Trevi Therapeutics, Inc. a real, registered company?
- Trevi Therapeutics, Inc. files with the SEC under CIK 1563880 (its SEC filings).
- Its shares are listed under the ticker TRVI on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in New Haven, Connecticut, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Trevi Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Trevi Therapeutics, Inc.'s owners and officers?
Trevi Therapeutics, Inc.: incorporated in Delaware; business address in New Haven, Connecticut; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-27 | Blackrock, Inc. | 6.9% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 8.8% |
| Schedule 13D/A, 2026-05-07 | New Enterprise Associates 16, L.P. | 10.5% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 6.3% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-13 | Rubric Capital Management LP | 2.94% |
| Schedule 13D/A, 2026-02-13 | New Enterprise Associates 16, L.P. | 11.6% |
| Schedule 13G, 2026-02-05 | Fmr LLC | 5.1% |
| Schedule 13G, 2026-01-30 | The Vanguard Group | 5.01% |
| Schedule 13G/A, 2025-11-14 | Frazier Life Sciences Public Fund, L.P. | 7% |
| Schedule 13G/A, 2025-11-14 | Viking Global Investors LP | 4.2% |
| Schedule 13G, 2025-10-17 | Blackrock, Inc. | 5.6% |
Questions about who owns Trevi Therapeutics, Inc.
Who owns Trevi Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Trevi Therapeutics, Inc.: New Enterprise Associates 16, L.P. (10.5%, Schedule 13D/A, filed 2026-05-07), Fmr LLC (8.8%, Schedule 13G/A, filed 2026-08-06), Frazier Life Sciences Public Fund, L.P. (7%, Schedule 13G/A, filed 2025-11-14) and Blackrock, Inc. (6.9%, Schedule 13G/A, filed 2026-10-27).
Who are the largest shareholders of Trevi Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Trevi Therapeutics, Inc. on this page are New Enterprise Associates 16, L.P. (10.5%), Fmr LLC (8.8%) and Frazier Life Sciences Public Fund, L.P. (7%).
When did New Enterprise Associates 16, L.P. buy into Trevi Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from New Enterprise Associates 16, L.P. on this page is the Schedule 13D/A, filed 2026-02-13, reporting 11.6%; its latest, Schedule 13D/A filed 2026-05-07, reports 10.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Trevi Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Trevi Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Trevi Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Trevi Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 13,222,228 shares (9.3% of shares outstanding), held indirectly through a see note 1 (Form 5, 2026-02-13).
- , a 10% owner: 13,222,228 shares (9.3% of shares outstanding), held indirectly through a see note 1 (Form 5, 2026-02-13).
- , a 10% owner: 13,222,228 shares (9.3% of shares outstanding), held indirectly through a see note 1 (Form 5, 2026-02-13).
- , a 10% owner: 13,222,228 shares (9.3% of shares outstanding), held indirectly through a see note 1 (Form 5, 2026-02-13).
- , a 10% owner: 13,222,228 shares (9.3% of shares outstanding), held indirectly through a see note 1 (Form 5, 2026-02-13).
Shares outstanding: 142,559,400 as of 2026-10-31, from the company's latest SEC cover page.
How much has Trevi Therapeutics, Inc. raised?
No fundraising or offering filing from Trevi Therapeutics, Inc. is on file with us.
Keep reading
More on Trevi Therapeutics, Inc. and the records around it.
Trevi Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- New Enterprise Associates 16, L.P. also filed stake reports on 1 other company: Marker Therapeutics, Inc. (Nov 2025)
- Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: PHATHOM PHARMACEUTICALS, INC. (Nov 2026), Q32 Bio Inc. (Oct 2026), ACLARIS THERAPEUTICS, INC. (Sep 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/trevi-therapeutics